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Outcome of Drug-Eluting Versus Bare-Metal Stenting
Used According to On- and Off-Label Criteria
Jörg Carlsson, MD, PHD,* Stefan K. James, MD, PHD,† Johan Lindbäck, PHD,†
Fredrik Scherstén, MD, PHD,‡ Tage Nilsson, MD, PHD,† Ulf Stenestrand, MD, PHD,§
Bo Lagerqvist, MD, PHD,† for the SCAAR (Swedish Coronary Angiography and
Angioplasty Registry) Study Group
Kalmar, Uppsala, Helsingborg, and Linköping, Sweden
Objectives The aim of this study was to investigate the outcome of bare-metal stents (BMS) versus drug-eluting stents
(DES) after on-label as well as off-label use.
Background DES lower restenosis rates while not influencing the risk for death and myocardial infarction when used in Fed-
eral Food and Drug Administration (FDA)-approved indications. It is debated whether the clinical results of this
so-called on-label use might be extrapolated to off-label situations.
Methods The SCAAR (Swedish Coronary Angiography and Angioplasty Registry) was used to investigate the outcomes in
17,198 patients who underwent stenting with an on-label indication (10,431 BMS and 6,767 DES patients) and
16,355 patients in the context of an off-label indication (9,907 BMS and 6,448 DES patients). The patients were
included from 2003 to 2005 with a minimum follow-up of 1 year and a maximum of 4 years. The analysis was
adjusted for differences in baseline characteristics.
Results There were not significant differences between on-label DES and BMS (adjusted hazard ratio: 1.02; 95% confi-
dence interval: 0.92 to 1.13) or between off-label DES and BMS (adjusted hazard ratio: 0.95; 95% confidence
interval: 0.87 to 1.04) use with regard to the incidence of myocardial infarction and death. Off-label use of DES
did not lead to significant differences in the combined risk of death and myocardial infarction compared with
BMS throughout the whole spectrum of clinical indications.
Conclusions In contemporary Swedish practice, neither on- nor off-label use of DES is associated with worse outcome than
use of BMS. (J Am Coll Cardiol 2009;53:1389–98) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.067a
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ohe U.S. Food and Drug Administration (FDA) approved
he use of the sirolimus-eluting stent (SES) in April 2003
nd the paclitaxel-eluting stent in March 2004. The ap-
roval was based on a number of pivotal randomized clinical
rials investigating relatively low-risk clinical situations and
herefore consequently limited to these indications as spec-
fied in the product labeling. Despite a rather limited
umber of “on-label” indications, the use of drug-eluting
tents (DES) increased over the years to more than 80% of
rom the *Department of Internal Medicine, Division of Cardiology, Kalmar County
ospital, Kalmar, Sweden; †Uppsala Clinical Research Center, Uppsala University
ospital, Uppsala, Sweden; ‡Department of Cardiology, Helsingborg Hospital, Hels-
ngborg, Sweden; and the §Department of Cardiology, Linköping University Hospital,
inköping, Sweden. The SCAAR (Swedish Coronary Angiography and Angioplasty
egistry) and the Uppsala Clinical Research Centre (UCR) are funded by the
wedish Association of Local Authorities and Regions and the Swedish Heart
oundation. This study was also sponsored by a grant from the Swedish Board of
ealth and Welfare and the Swedish Medical Products Agency.t
Manuscript received June 5, 2008; revised manuscript received August 8, 2008,
ccepted September 18, 2008.ll stent procedures in some countries and was widespread,
xtending to “off-label” indications. First, in 2006, when
everal clinical investigations into real-world practice pointed
oward specific risks with the use of DES—namely late
tent thrombosis—the issue of on-label versus off-label
ndications was re-examined. In December 2006 an FDA
earing concluded, on the basis of all available evidence
ncluding a large number of meta-analyses, that on-label
ES use is not associated with increased incidence of
yocardial infarction (MI) or death, although it is associ-
ted with increased rates of very late stent thrombosis.
ff-label use, in contrast, was thought to be associated with
higher risk of death or MI when compared with on-label
se (1–3). This fact might be due to a patient population
ith a higher risk. Although the early data (2003 and
004) of SCAAR (Swedish Coronary Angiography and
ngioplasty Registry) pointed toward a higher risk of death
r MI associated with DES compared with BMS use (4),
his difference could no longer be seen after the inclusion of
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On- and Off-Label Use of Stents April 21, 2009:1389–98the 2005 cohort of patients (5).
Both analyses were based on a
mixture of on- and off-label use
in daily practice. The present re-
port evaluates the long-term out-
come of all patients who under-
went stent implantation in
Sweden from 2003 to 2005 with
regard to on- versus off-label use
of DES and BMS.
Methods
Study population. The present
study included all patients in Swe-
den who had undergone coronary
stenting from January 1, 2003, un-
til December 31, 2005 for whom
at least 1 year of follow-up was
available by merging with other
national registries. The analyses
were based on the type of stent
mplanted at the first recorded procedure, where patients receiving
t least 1 DES were assigned to the DES group regardless of
hether they received a stent of another type at any time;
therwise they were assigned to the BMS group.
he SCAAR registry. The SCAAR registry records con-
ecutive patients from all centers (n  27) performing
oronary angiography and percutaneous coronary interven-
ions (PCIs) in Sweden. All consecutive patients undergo-
ng coronary angiography and/or PCI are included. Infor-
ation on restenosis has been registered for patients
ndergoing a subsequent coronary angiography for clinical
easons since the beginning of 2004.
The long-term follow-up was based on merging the
CAAR database with other National registries based on all
wedish citizens’ unique 10-digit personal identification
umber. Vital statistics and date of death were obtained
rom the National Population registry until September 15,
007. Hospital admission for MI (International Classifica-
ion of Diseases-10th edition: I21 and I22) was obtained
rom the Swedish Hospital Discharge Registry until De-
ember 31, 2006. The merging of the registers was per-
ormed by the Epidemiologic Centre of the Swedish Na-
ional board of Health and Welfare and approved by the
ocal ethics committee at the Uppsala University.
esign and aim of the present study. The information
tates that the “sirolimus-eluting coronary stent is indicated
or improving coronary luminal diameter in patients with
ymptomatic ischemic disease due to discrete de novo
esions of length 30 mm in native coronary arteries with
eference vessel diameter of 2.5 mm to 3.5 mm” (6).
The paclitaxel-eluting coronary stent system is indicated
or improving luminal diameter for the treatment of de novo
esions 28 mm in length in native coronary arteries 2.5
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
IQR  interquartile range
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RR  relative risk
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarctiono3.75 mm in diameter” (7). Patients in the present study (ere divided into 2 groups on the basis of the following
efinitions for “on-label” use: stent length 33 mm, diam-
ter 2.5 and 3.75 mm, de novo lesions, non–ST-
egment elevation acute myocardial infarction, no occlusion
lder than 3 months, no grafts, no cardiogenic shock, and
ot more than 2 stents in the same vessel. All other patients
ere assigned to the off-label group.
Then patients were then analyzed according to whether
hey received 1 or more DES or 1 or more BMS. Please
ote that for grouping of the BMS patients the same DES
efinitions for on- and off-label situations were used and
anufacturer information about the labeled use of BMS
as not taken into account for the purposes of this investi-
ation. This led to 4 main groups of patients: DES patients
ith an on- or off-label indication, and BMS patients with an
n- or off-label indication for stenting.
The primary aim of the investigation was to compare the
utcome after DES off-label stenting versus BMS off-label
tenting. Secondary aims included the comparison of on-
abel BMS stenting versus on-label DES stenting. Further-
ore, we aimed to compare on-label versus off-label stent-
ng irrespective of stent type.
tatistical analyses. The statistical methods used for this
nalysis have been published in detail in an earlier article
bout DES use in Sweden (4). Baseline characteristics were
ummarized with medians and interquartile ranges for
ontinuous variables and percentages for discrete variables.
umulative event rates were estimated by the Kaplan-Meier
ethod. The primary objective was to evaluate late occur-
ing events after stenting. The primary end point was the
omposite of death or MI. Secondary end points were
eath, MI, revascularization, and restenosis. Clinically im-
ortant confounders (as presented in Table 1) were sum-
arized in a propensity score (8). Separate propensity
cores were estimated for the on- and off-label groups by
tting multiple logistic regression models. To evaluate
hether the propensity score managed to balance the
roups as regards the included variables, standardized
eans were calculated and compared before and after
ropensity score adjustment. Adjusted relative risks
RRs) were estimated from models where the propensity
core and stent group were entered as covariates. For
lotting purposes the models were then refitted with
tent group as a stratification variable, and adjusted
umulative event rates were estimated at the overall
verage propensity score. Death was regarded as a cen-
oring event in the analysis of MI. All analyses were done
ith the statistical program R version 2.6.1 (9).
esults
atient characteristics and stents. During the years 2003
o 2005, 34,530 patients underwent stenting in Sweden. A
otal of 977 patients (2.8%) were excluded due to missing
ata about important baseline characteristics. Thus, 33,553
97.2%) patients were included in the study and listed in
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April 21, 2009:1389–98 On- and Off-Label Use of Stentsable 1. Of the patients, 10,431 received at least 1 BMS but
o DES, and 6,767 received at least 1 DES in an on-label
ituation; 9,907 patients received 1 or more BMS, and 6,448
aseline Characteristics
Table 1 Baseline Characteristics
On-Label
BMS (n  10,431) DE
Age, yrs, median (IQR) 66 (58–74)
Female sex 29.3 (3,053) 2
Region
North 17.4 (1,810)
Stockholm 19.5 (2,029) 1
Southeast 9.6 (1,002) 1
South 13.6 (1,420) 2
Middle 23.2 (2,422) 4
West 16.8 (1,748)
Year
2003 39.6 (4,128) 1
2004 34.7 (3,615) 3
2005 25.8 (2,688) 4
Stable CAD 27.8 (2,895) 3
Unstable CAD 71.1 (7,415) 6
STEMI
Other indications 1.2 (121)
Smoking
Current 19.8 (2,066) 1
Former 33.4 (3,480) 3
Never 38.1 (3,972) 4
Unknown 8.8 (913)
Diabetes 16.0 (1,670) 2
Hypertension 47.7 (4,980) 4
Unknown 2.0 (213)
Previous heart failure 7.1 (744)
Previous kidney failure 1.0 (107)
Previous dialysis 0.4 (43)
Previous COPD 4.8 (496)
Previous dementia 0.1 (8)
Previous cancer 2.5 (256)
Previous PCI 10.5 (1,094) 1
Previous CABG 6.5 (677)
Previous MI 39.4 (4,114) 3
Previous stroke 5.6 (585)
ASA before 92.0 (9,597) 9
Clopidogrel before 66.1 (6,895) 7
GP IIb/IIIa inhibitors 24.9 (2,596) 2
No. of stents
1 73.2 (7,631) 6
2 22.7 (2,372) 2
3 4.1 (428)
Angiographic findings
Not significant 0.3 (28)
1-vessel 52.9 (5,514) 4
2-vessel 30.7 (3,202) 3
3-vessel 14.9 (1,556) 1
Left main 1.3 (131)
alues shown as % (n) unless otherwise stated.
ASA  acetyl-salicyl acid; BMS  bare-metal stent(s); CABG  coronary artery bypass graft; CAD
P  glycoprotein; IQR  interquartile range; MI  myocardial infarction; PCI  percutaneous coeceived 1 or more DES for an off-label indication. There- Bore, off-label clinical situations accounted for 49% of all
ES use in the observation period (with little variation
etween 47.4% in 2003 and 50.0% in 2005), whereas of all
Off-Label
6,767) BMS (n  9,907) DES (n  6,448)
8–73) 66 (58–75) 66 (58–74)
,991) 25.1 (2,486) 27.8 (1,790)
35) 9.3 (925) 2.5 (160)
,170) 17.8 (1,766) 13.7 (881)
96) 7.7 (764) 12.1 (778)
,624) 21.2 (2,104) 30.2 (1,948)
,749) 24.5 (2,431) 38.3 (2,469)
93) 19.3 (1,917) 3.3 (212)
,125) 31.4 (3,110) 15.7 (1,015)
,312) 36.9 (3,653) 32.4 (2,091)
,330) 31.7 (3,144) 51.8 (3,342)
,171) 14.3 (1,418) 26.8 (1,731)
,490) 27.6 (2,730) 38.4 (2,474)
58.0 (5,747) 34.4 (2,219)
06) 0.1 (12) 0.4 (24)
,208) 23.6 (2,337) 20.5 (1,322)
,230) 28.6 (2,836) 30.8 (1,984)
,844) 33.1 (3,282) 39.5 (2,549)
85) 14.7 (1,452) 9.2 (593)
,580) 15.5 (1,540) 23.3 (1,502)
,273) 41.4 (4,104) 46.7 (3,010)
48) 4.1 (408) 3.8 (248)
03) 6.5 (647) 8.0 (514)
8) 1.0 (95) 1.3 (85)
2) 0.3 (34) 0.5 (34)
06) 4.7 (464) 4.4 (282)
) 0.1 (8) 0.1 (4)
68) 2.7 (266) 2.5 (162)
57) 10.0 (990) 18.3 (1,180)
48) 12.2 (1,206) 15.1 (971)
,451) 33.5 (3,317) 38.7 (2,495)
06) 6.6 (649) 6.7 (429)
,396) 84.6 (8,384) 89.0 (5,738)
,826) 49.7 (4,923) 63.0 (4,063)
,401) 54.9 (5,434) 38.5 (2,480)
,224) 60.9 (6,033) 43.9 (2,833)
,013) 23.4 (2,323) 28.9 (1,863)
30) 15.7 (1,551) 27.2 (1,752)
0) 0.3 (28) 0.2 (15)
,328) 43.6 (4,318) 38.4 (2,473)
,188) 29.3 (2,905) 31.3 (2,020)
,130) 20.7 (2,046) 21.7 (1,396)
1) 6.2 (610) 8.4 (544)
nary artery disease; COPD  chronic obstructive pulmonary disease; DES  drug-eluting stent(s);
intervention; STEMI  ST-segment elevation myocardial infarction.S (n 
65 (5
9.4 (1
3.5 (2
7.3 (1
1.8 (7
4.0 (1
0.6 (2
2.9 (1
6.6 (1
4.2 (2
9.2 (3
2.1 (2
6.4 (4
1.6 (1
7.9 (1
3.0 (2
2.0 (2
7.2 (4
3.3 (1
8.4 (3
2.2 (1
7.4 (5
1.3 (8
0.8 (5
4.5 (3
0.0 (3
2.5 (1
1.2 (7
6.6 (4
6.2 (2
6.0 (4
4.5 (6
1.3 (4
0.7 (1
2.4 (4
9.7 (2
7.8 (5
0.4 (3
9.2 (3
2.3 (2
6.7 (1
1.3 (9MS that were implanted 49% were used for off-label
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On- and Off-Label Use of Stents April 21, 2009:1389–98ndications. The average DES usage increased continuously
uring the study period, from 12% the first quartile of 2003
o 59% the fourth quartile of 2005. On-label indications
ncreased the use of DES from 21.4% in 2003 to 55.3% in
005, whereas in off-label situations the DES use was 24.6%
n 2003 and 51.5% in 2005.
Table 1 shows patient characteristics in the on- and
ff-label groups, divided by BMS and DES.
The DES group was, on average, slightly younger and
ad higher proportions of diabetes mellitus compared with
he BMS cohort, with regard to on-label situations. Previ-
us MI was less often observed in the DES group, whereas
revious PCI was more frequently registered. Multivessel
nd left main disease was more frequently observed in the
ES group.
In both on- and off-label clinical situations, clopidogrel
se before the procedure was more prevalent in the DES
roups. Periprocedural glycoprotein IIb/IIIa inhibition was
ess common in the DES group, and this difference was
ighly significant in off-label indications, because of the
nclusion of ST-segment elevation myocardial infarction
STEMI) patients. STEMI was also the single second-most-
mportant criterion that led to inclusion in the DES off-label
roup, whereas the single most-important criterion was
tent diameter 2.5 or 3.75 mm, followed by 2 stents/
essel, chronic occlusion, and restenotic lesion (Table 2).
After adjustment for the propensity score the DES and
MS groups were well balanced in both the on- and
ff-label situations (data not shown).
eath and MI. During the entire study period, 4,845
atients experienced an MI and/or died (1,255 in the
n-label BMS group, and 761 in the on-label DES group;
,836 in the off-label BMS group, and 993 in the off-label
ES group).
During the entire study period, 6,660 events occurred,
,602 MIs (956 in the on-label BMS group, and 628 in the
n-label DES group; 1,223 in the off-label BMS group, and
95 in the off-label DES group) and 3,058 deaths (785 in
he on-label BMS group, and 456 in the on-label DES
roup; 1,191 in the off-label BMS group, and 626 in the
ff-label DES group). The mean follow-up for the com-
requency of Different Off-Label Criteria
Table 2 Frequency of Different Off-Label Criteria
Criteria
BMS
(n  9,907)
DES
(n  6,448)
All
(n  16,355)
STEMI 5,747 (58.0%) 2,219 (34.4%) 7,966 (48.7%)
Stent diameter 2.5 or
3.75 mm
3,393 (34.2%) 2,552 (39.6%) 5,945 (36.3%)
Stent length 33 mm 60 (0.6%) 24 (0.4%) 84 (0.5%)
More than 2 stents/
coronary vessel
1,118 (11.3%) 1,102 (17.1%) 2,220 (13.6%)
Stented chronic occlusion 462 (4.7%) 712 (11.0%) 1,174 (7.2%)
Stented CABG graft 761 (7.7%) 433 (6.7%) 1,194 (7.3%)
Stented restenotic lesion 210 (2.1%) 607 (9.4%) 817 (5.0%)
Stented left main lesion 139 (1.4%) 248 (3.8%) 387 (2.4%)(bbreviations as in Table 1.ined end point MI/death was 785 days (743 days for
ff-label use, and 825 days for on-label use).
There was no significant difference between the DES and
MS groups in the composite of death and MI during the
years follow-up period. This was true for on-label as well
s off-label indications (Figs. 1 and 2).
ortality. The total number of deaths was 3,058 (785 in
he on-label BMS group, and 456 in the on-label DES
roup; 1,191 in the off-label BMS group, and 626 in the
ff-label DES group). There was not a difference in the
umulative adjusted mortality between DES and BMS in
n-label situations or in off-label situations (Figs. 3 and 4).
The mean follow-up for the end point death was 1,069 days
1,029 days for off-label use, and 1,107 days for on-label use).
I. The total number of patients experiencing at least 1
I was 2,851 (773 in the on-label BMS group, and 494 in
he on-label DES group; 988 in the off-label BMS group,
nd 596 in the off-label DES group). There was no
ifference between DES and BMS use in on-label or
ff-label situations over a period of 4 years. The RR for
n-label use of DES was 1.00 (95% confidence interval
CI]: 0.87 to 1.14), whereas it was 0.97 (95% CI: 0.86 to
.09) for off-label stenting (Figs. 5 and 6).
estenosis and new revascularization. During follow-up,
n the on-label group the crude rate of restenosis/year of
ollow-up was 3.0% for BMS (n  319) and 1.8% for DES
n  173), whereas in the off-label group the crude rates
ere 3.4%/year for BMS (n  379) and 2.7%/year for DES
Figure 1 Death or MI: On-Label
Propensity score adjusted cumulative event rates regarding the composite of
death or myocardial infarction (MI) during 4 years of follow-up after stenting for
on-label indications with drug-eluting stents (DES) (dashed line) or with bare-
metal stents (BMS) only (solid line). Numbers at risk are shown below each
figure. RR  relative risk.n  246). The RR to develop a restenosis associated with
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April 21, 2009:1389–98 On- and Off-Label Use of StentsES use was 0.57 (95% CI: 0.46 to 0.70) for on-label
ndications and 0.79 (95% CI: 0.65 to 0.96) for off-label
ndications after adjusting for differences in baseline char-
cteristics through the propensity score.
Figure 2 Death or MI: Off-Label
Propensity score adjusted cumulative event rates regarding the composite of
death or MI during 4 years of follow-up after stenting for off-label indications
with DES (dashed line) or with BMS only (solid line). Numbers at risk are
shown below each figure. Abbreviations as in Figure 1.
Figure 3 Mortality: On-Label
Propensity score adjusted cumulative mortality rates during 4 years of follow-up
after stenting for on-label indications with DES (dashed line) or with BMS only
(solid line). Numbers at risk are shown below each figure. Abbreviations as in
Figure 1.In the on-label BMS group, 1,481 patients (6.2%/year of
ollow-up) had new PCI, and 218 patients (0.8%/year)
nderwent coronary artery bypass graft surgery (CABG)
uring follow-up; in the on-label DES group, 995 (8.0%/
Figure 4 Mortality: Off-Label
Propensity score adjusted cumulative mortality rates during 4 years of follow-up
after stenting for off-label indications with DES (dashed line) or with BMS only
(solid line). Numbers at risk are shown below each figure. Abbreviations as in
Figure 1.
Figure 5 MI During Follow-Up: On-Label
Propensity score adjusted cumulative rates of MI during 4 years of follow-up
after stenting for on-label indications with DES (dashed line) or with BMS only
(solid line). Numbers at risk are shown below each figure. Abbreviations as in
Figure 1.
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On- and Off-Label Use of Stents April 21, 2009:1389–98ear) had new PCI, and 106 (0.8%/year) underwent CABG
uring follow-up. In the off-label BMS group, the corre-
ponding numbers were 1,672 (8.4%/year) for new PCI and
68 (1.6%/year) for CABG. In the off-label DES group, the
orresponding numbers were 1,126 (10.3%/year) for new
CI and 162 (1.3%/year) for CABG.
esults according to indication. There were, in total,
,215 patients with an indication of stable coronary artery
isease (CAD), of which 5,066 (61.7%) fulfilled on-label
riteria. The RR for the combined end point of death or MI
ssociated with the use of DES in on-label situations was
.93 (95% CI: 0.75 to 1.16), whereas that number for
ff-label stent usage was 0.95 (95% CI: 0.75 to 1.20)
Fig. 7). There was no statistically significant difference
etween BMS and DES regarding the end point of MI
hen looking at stable CAD for either the on-label situa-
ions with an RR of 0.83 (95% CI: 0.63 to 1.10) or the
ff-label situation with an RR of 0.98 (95% CI: 0.72 to
.33). In addition, there were no differences in the end point
f death between DES and BMS in stable patients, either in
n- or off-label situations.
The biggest subgroup was patients with unstable CAD
unstable angina and non–ST-segment elevation acute
yocardial infarction) with a total of 17,109 patients. Of
hose, 11,905 (69.6%) were treated in an on-label situation.
hen looking at the issue of BMS versus DES in on- and
ff-label situations regarding the different end points of
eath, death and MI, and MI alone, there were no statis-
ically significant differences in outcome between the 2 types
Figure 6 MI During Follow-Up: Off-Label
Propensity score adjusted cumulative rates of MI during 4 years of follow-up
after stenting for off-label indications with DES (dashed line) or with BMS only
(solid line). Numbers at risk are shown below each figure. Abbreviations as in
Figure 1.f stents. The adjusted hazard ratio for the combined endoint of death or MI was 1.05 (95% CI: 0.93 to 1.19) in
n-label situations and 1.00 (95% CI: 0.86 to 1.16) in
ff-label situations (Fig. 8).
STEMI was the single most important criterion to
ualify a patient undergoing stenting as off-label (7,966
atients in total, accounting for 48.7% of all patients in the
ff-label group). There were 5,747 patients in the BMS
roup (58.0% of off-label BMS use) and 2,219 patients
34.4% of off-label DES use) in the DES group. As direct
CI for STEMI became more accepted under the study
eriod, the use of DES stents increased in this off-label
linical situation from approximately 15% in 2003 to 36% in
005. The RR for death associated with DES was 0.99
95% CI: 0.85 to 1.16) during 4 years of follow-up for
TEMI patients. Neither the combined end point of MI
nd death (RR: 0.92; 95% CI: 0.81 to 1.04) (Fig. 9) nor MI
lone (RR: 0.93; 95% CI: 0.78 to 1.11) showed a significant
ifference between DES and BMS during the entire study
eriod of 4 years.
iscussion
n the present study we evaluated the long-term outcome
ith DES versus BMS in a large cohort of unselected
onsecutive patients treated with coronary stenting at all
nterventional centers in Sweden. The patients were
rouped according to the on- or off-label use of DES and
ompared with a corresponding control group of BMS
atients with the same labeling categories from DES as
tated in the manufacturers’ information for use, which is
Figure 7 Event Rates for Stable
Coronary Artery Disease: Off-Label
Propensity score adjusted cumulative event rates of death or MI during 4 years
of follow-up after stenting with DES (dashed line) or with BMS only (solid line)
for off-label indications. Numbers at risk are shown below each figure. Abbrevi-
ations as in Figure 1.
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April 21, 2009:1389–98 On- and Off-Label Use of Stentsased on the FDA approval. The FDA approval is based on
he so-called pivotal trials that led to the introduction of
ES. Despite the fact that the database for DES use in
ff-label situations is sparse, this use is estimated to com-
rise more than 60% of all DES use in the U.S. (1), and it
as 49% in the present investigation. This figure fits well
ith other publications that reported between 47% (10) and
5% (11) off-label DES use.
Although we showed that death and MI are more
revalent during follow-up after off-label stenting compared
ith on-label use of stents, this finding was neither unex-
ected nor the main purpose of our investigation. Most
nformation from the published data regarding off-label use
f DES comes from registries that represent a mixture of
n- and off-label indications (12–17), and none found a
ifference between BMS and DES with regard to mortality
nd MI, which is in accordance with meta-analyses of on-
nd off-label randomized trials (18). Our own analysis of the
wedish data from 2003 to 2004 was also a mixture of on-
nd off-label usage, and many analysts thought the negative
esults for DES were mainly due to off-label DES use (4).
n analysis of patients included from 2003 to 2005 could
ot find the same differences between stent types without
xamining the on- versus off-label issue (5).
One of the registries that included all patients specifically
nvestigated lesion characteristics that constitute off-label
ES-use and did not find any difference between DES and
MS use with regard to death and MI at 1 year (17). That
Figure 8 Event Rates for Unstable
Coronary Artery Disease: Off-Label
Propensity score adjusted cumulative event rates of death or MI during 4 years
of follow-up after stenting with DES (dashed line) or with BMS only (solid line)
for off-label indications. Numbers at risk are shown below each figure. Abbrevi-
ations as in Figure 1.egistry included even lesion characteristics that we couldot take into account, like bifurcation lesions, presence of
alcification, and thrombus (17). Abbott et al. (17) did not
eport any significant differences between DES and BMS
ith regard to mortality and MI during 1 year of follow-up.
None of the other mentioned registries investigated the
n- versus off-label issue with regard to differences between
MS and DES.
Four registry reports focused on off-label DES use and
ompared clinical outcome data with on-label DES use
10,11,19,20). The off-label DES use accounted for be-
ween 24.1% (19) and 65.1% (20) in these studies. Two
eports showed that the safety and efficacy of DES is
educed in off-label indications as compared with on-label
se (10,11) while judging these results differently. One of
hem, the EVENT (Evaluation of Drug Eluting Stents and
schemic Events) registry, did not include STEMI patients
nd did not report significant differences in mortality
etween the 2 groups, either during index admission or
uring 12 months of follow-up (10). Myocardial infarction,
owever, was more prevalent in the off-label DES group
ompared with the on-label DES group, and this difference
as significant both during the index admission and 12
onths of follow-up (10). When considering these results,
owever, it must be taken into account that Win et al. (10)
ystematically measured biomarkers and even excluded
,019 patients (23.5%) because of missing baseline markers.
ff-label use was also an independent predictor in multi-
ariate analysis of worse outcome both during index hospital
tay and during follow-up (10). The EVENT registry (10)
s well as the D.E.S.cover registry (11) are limited by the
Figure 9 Event Rates for STEMI Patients: Off-Label
ST-segment elevation myocardial infarction (STEMI). Propensity score adjusted
cumulative event rates of death or MI during 4 years of follow-up after stenting
with DES (dashed line) or with BMS only (solid line). Numbers at risk are
shown below each figure. Abbreviations as in Figure 1.
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On- and Off-Label Use of Stents April 21, 2009:1389–98ermination of follow-up at 1 year (21); the level of events
as rather low in both registries, which reported mortality
ates at 1 year of 3.1% (10) and 4.3% (11), respectively, for
ff-label DES use. Mortality rates were lower for on-label
ES use and were reported with 2.1% (10) and 2.6% (11),
espectively. The crude mortality in our study after 1 year
as much higher at 5% for on-label DES use and 7% for
ff-label DES use. We did not exclude—in contrast to the
ther registries—any patients from our analysis, especially
ot STEMI patients, like Win et al. (10) did.
Clinically, it might not be helpful to compare outcome
fter DES in on-label indications with outcome after
ff-label DES. The general opinion of commentators was
hat, despite the fact that on-label results obviously cannot
e extrapolated to off-label use, the absolute number of
hort- to medium-term adverse events after off-label DES
se is low. Furthermore, the significant reduction of target
essel revascularization even in off-label situations when
ompared with historical controls (17) or model data (18)
ontributes to the recommendation to use DES generally (21).
When discussing the issue of off-label DES use, it seems
ore important to compare results between off-label DES
se and off-label BMS use. Drug-eluting stents have been
hown in a number of trials that addressed single off-label
ndications to reduce the rates of restenosis, target vessel
evascularization, and major adverse cardiac events (22–24).
owever, none of these trials was designed to show mor-
ality differences, and most trials were hampered by exclu-
ion criteria and short follow-up (21). In a meta-analysis of
ifferent randomized trials of off-label SES use versus
ff-label BMS use, Kastrati et al. (25) reported an RR
ssociated with SES of 0.97 (95% CI: 0.70 to 1.33) for
eath and 0.88 (95% CI: 0.51 to 1.52) for stent thrombosis.
hey concluded that there was no evidence that off-label use
f SES is associated with compromised safety compared
ith BMS (25). Although they concluded this from several
andomized trials—some as little as including 83 patients in
otal—the message is in accordance with the presented data
rom Sweden, although we did not differentiate between
ES and paclitaxel-eluting stent.
Three newer publications, 1 from a multi-center registry
26) and 2 from monocentric observations (27,28), investi-
ated specifically the issue of BMS versus DES usage in
ff-label indications. All used historical control data for
MS outcome, and follow-up was between 1 (26,27) and 2
ears (28), and all found that DES lowered significantly
he rate of target vessel revascularization compared with
MS. Although 2 of the publications (26,27) did not
nd—in concurrence with our study—any significant dif-
erences in the outcome of death or MI between DES and
MS in off-label indications, 1 monocentric study with 854
istorical BMS patients and 993 DES patients found that
ES usage in off-label situations was associated with a
ignificant lower incidence of death and MI during
ollow-up (28). However, there is always a problem com- (aring historical data, because interventions and adjunctive
herapy tend to improve outcome in more recent years.
The rate of restenosis of between 1.8%/year (on-label
ES) and 3.4%/year (off-label BMS) in our material is, as
n all clinically driven investigations, much lower than in
andomized studies with an angiographic end point. Pa-
ients benefit from DES in both on-label as well as off-label
ndications; however, the reduction of restenosis was greater
or on-label indications. Because there are no registry data
omparing these groups of patients in daily clinical practice,
he reported numbers are not easily put into perspective.
ecause we cannot report on target lesion revascularization,
he data on repeat angioplasty and CABG have to be
nterpreted with caution and cannot be used in the discus-
ion about benefits of DES versus BMS. The numbers are
n the same range as the reported on-label/off-label mixture
ata from Abbott et al. (17). Patient selection bias led to the
nding that these rates are virtually not comparable between
ES and BMS use in both labeling groups.
The analysis of the indication groups’ stable CAD and
nstable CAD confirms the safety of DES compared with
MS in on- and off-label situations with no differences in
utcome between stent types.
In Sweden the use of DES in the situation of STEMI
ncreased from 15% in 2003 to 36% in 2005 and was far
ower than in the U.S., with a reported increase from 18%
n 2003 to 85% in 2005 (29). In contrast to many other
ff-label indications, the use of DES in the context of
TEMI has been investigated in many randomized trials,
nd even 2 meta-analyses of some of these trials have been
ublished (30,31). Both meta-analyses came to the same
onclusion—that the use of DES in patients with STEMI
s safe and improves clinical outcomes. The total number of
atients was higher in the publication of Kastrati et al. (31)
nd allowed analysis of DES 1,474 patients and 1,312 BMS
atients in a total of 8 randomized clinical trials. However,
he follow-up was limited to 12 months in 5 of the 8 trials
31). The investigation of late events, namely MI and death
ue to late stent thrombosis, is therefore limited by study
esign (31). Another shortcoming of the meta-analyses is
hat exclusion criteria were usually present and therefore the
esults cannot easily be applied to an all-comers infarct
opulation. It has already been pointed out (32) that the
nly trial that did not exclude many patients because of
linical and lesion characteristics, the PASSION (Paclitaxel
luting Stent Versus Conventional Stent in ST-segment
levation Myocardial Infarction) trial (33), did not show an
dvantage in target lesion revascularization for DES versus
MS. We did not find a significant difference between DES
nd BMS when looking at the entire follow-up period of 4
ears. A very late risk with DES cannot totally be ruled out,
ue to the nature and limitations of a registry study. Such a
isk was seen in the RESEARCH (Rapamycin-Eluting
tent Evaluated At Rotterdam Cardiology Hospital) and
-RESEARCH registries (34) as well as in the GRACEGlobal Registry of Acute Coronary Events) registry (35).
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April 21, 2009:1389–98 On- and Off-Label Use of Stentslthough RESEARCH and T-RESEARCH did not re-
ort any differences in MI between SES and BMS after
years the earlier advantage for SES at 1 year disappeared
nder the following 2 years in part because of a higher rate
f late stent thromboses (34).
The GRACE registry delivered a totally different mes-
age than the randomized studies by finding an increased
ate of late mortality between 6 months and 2 years
ssociated with DES use, which also was thought to be
elated to late stent thrombosis (35). Whereas there was no
ifference in mortality at 6 months between DES (n 569)
nd BMS (n  1,729), GRACE reported late mortality of
.6% versus 1.6% (p  0.001) and a rate of late reinfarction
f 5.4% versus 2.9% (p  0.046), both to the disadvantage
f DES (35). Patients receiving a DES had a lower
n-hospital mortality compared with BMS patients, like in
ur study—a fact that is difficult to explain but most likely
epends on patient selection. So neither the randomized
rials nor the available registry data can totally take away the
uspicion of late clinical events due to late stent thrombosis
n DES, which according to other observational real-life
ata occurs with 0.5%/year with no tendency to abate (36).
onger follow-up than we could provide in the present
tudy might be needed to finally settle this question.
tudy limitations. The following untested situations ac-
ording to the manufacturers information were not regis-
ered in SCAAR over the whole time period and could
herefore not be analyzed in this investigation as off-label
riteria: heavily calcified lesions, highly tortuous anatomy,
ifurcation, left ventricular function 30%, and presence of
efinite or probable intraluminal thrombus (6,7).
Several other important limitations of the present study
equire comment. Bias in patient selection cannot be ruled
ut, as in all nonrandomized studies, although the statistical
ethods applied led to a good adjustment for all known
linical characteristics. However, nonrecorded characteris-
ics (e.g., left ventricular function) could not be adjusted for.
n contrast, the reported data represent daily clinical prac-
ice on an all-comers basis in a whole country with a 99.9%
ate of follow-up regarding death by using the national
opulation registry. In other words, this registry has some
nique features, such as coverage of all procedures,
ontrol by monitoring visits, and independence from indus-
ry support. The long-term follow-up, up to 4 years com-
ared with 1 year in most comparable publications (10,11),
lso strengthens this study.
The clinical advantages of DES, namely the reduction of
estenosis and repeated revascularization, cannot be appro-
riately addressed in a registry like ours. This is because
estenosis will only be diagnosed after clinically driven
eangiography and because we cannot differentiate between
estenosis and progress when it comes to repeated PCI.
Perhaps the most important limitation of the presented
ata is that we cannot provide data on the length of or
ompliance with dual-antiplatelet therapy. Dual-antiplatelet
herapy has repeatedly been pointed out to be associatedith outcome after DES (37–39). It cannot be estimated to
hat extent the results, especially DES, are influenced by
he shifting length of dual antiplatelet therapy from between
and 6 months in the beginning of the study period to 12
onths or even longer at the end. However, even this
imitation is a mirror of real life practice and thus shared by
lmost all large observational studies of this kind.
onclusions
n contemporary Swedish practice, neither on- nor off-label
se of DES is associated with worse outcome than use of
MS. This applies to the whole clinical spectrum of CAD.
The reduction of restenosis through the use of DES was
tatistically highly significant for both on- and off-label
ndications, but the clinical benefit was higher for on-label
ES compared with off-label usage.
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